Drug intelligence / Profile preview

compound 6e (Lanzhou University)

Development stage: Preclinical
Lead developer: Lanzhou University
Modality: Small Molecules

Overview

Compound 6e is a small molecule developed by Lanzhou University. It is an alpha-glucosidase inhibitor, intended for the treatment of diabetes. Alpha-glucosidase inhibitors work by delaying the digestion and absorption of carbohydrates, thereby helping to control postprandial blood glucose levels in individuals with diabetes.

Targets

Sucrase-Isomaltase

Beyond the preview

Go deeper on compound 6e (Lanzhou University).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on compound 6e (Lanzhou University).

Explore the full profile